BioSpace News Archive

Cabaletta Bio, Inc. today announced that it has agreed to sell, by way of an underwritten public offering, pre-funded warrants, in lieu of common stock.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme Services.

Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1).

Actinium Pharmaceuticals, Inc. today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression.

Jounce Therapeutics, Inc. today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.

HCW Biologics Inc. today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.

BioInvent International AB (“BioInvent”) (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, announces it has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, UK and KU Leuven, Belgium.

Alvotech announced that trading in its shares will move from the Nasdaq Iceland First North Growth market to the Nasdaq Iceland Main Market, starting December 8, 2022.